Clinical Science

FDA-Cleared Since 1979.
Used by Mayo Clinic.
Backed by 20,000+ Studies.

PEMF therapy is not new. It has 45 years of regulatory history, tens of thousands of peer-reviewed studies, and routine use at the world's most respected medical institutions. Here is the complete clinical picture.

1979
FDA Approved
20,000+
Studies
250M+
Patients
Mayo Clinic
Validated

The Technology

Not Electromagnetic
Radiation. Therapy.

Your body's cells carry electrical charges. Sodium, potassium, and chloride ions govern normal cell function — controlling energy production, signal transmission, and tissue repair. When injury or chronic inflammation disrupts this electrical balance, cells lose their ability to function and respond. The dysfunction compounds over time. The result is chronic pain, poor healing, and degenerative disease.

PEMF therapy delivers precisely calibrated pulsed electromagnetic fields that penetrate 20–30 cm deep into tissue. Unlike radiation, PEMF does not generate heat or biological risk. It resonates with the body's own electrical systems — restoring cellular balance, reactivating repair pathways, and triggering the body's natural healing cascade. Without drugs. Without surgery.

Ion Channel Activation

Restores Na⁺/K⁺/Cl⁻ balance disrupted by injury or chronic inflammation

ATP Production

Stimulates mitochondrial activity, increasing cellular energy by 150–200%

Growth Factor Release

Triggers IGF-1, VEGF, and BMP — the body's natural tissue regeneration signals

Anti-Inflammatory Effect

Reduces pro-inflammatory cytokines, breaking the chronic inflammation cycle

Independent Medical Review

Reviewed by a
Former WHO Executive.

"PEMF technology uses low-frequency pulsed magnetic fields for therapeutic purposes — primarily in pain management, orthopedic and neurological rehabilitation, fracture healing, and inflammation reduction. The technology has been FDA-approved since 1979 and is in routine use at leading centers worldwide, including Mayo Clinic and the U.S. Military."

"The technology affects the body at the cellular and molecular level — ion channels, mitochondrial activity, growth factor secretion (IGF-1, VEGF, BMP), ATP production, and reduction of pro-inflammatory cytokines. The scientific evidence, regulatory approvals, and clear economic advantages point to high potential for integrating PEMF as an integral part of clinical rehabilitation programs."

IG
Prof. Itamar Grotto, MD

Former Deputy Director-General, Israeli Ministry of Health · Head of Public Health Services (10+ years) · Former WHO Executive Board Representative

Regulatory History

45 Years of
FDA Approval.

79
1979
First FDA Approval — Non-Union Bone Fractures

PEMF becomes the first electromagnetic therapy to receive FDA clearance, specifically for the treatment of non-healing bone fractures.

87
1987
Extended Approval — Cervical Fusion & Post-Surgical Pain

FDA extends clearance to cervical fusion failure and post-surgical pain management, broadening PEMF's clinical application.

98
1998
Class III Medical Device Status Confirmed

PEMF devices are formally classified under the FDA's Class III medical device framework, alongside pacemakers and other life-sustaining equipment.

04
2004
Mayo Clinic Proceedings Publishes PEMF Efficacy Study

One of the world's most respected medical journals publishes a landmark PEMF study, confirming therapeutic efficacy across multiple indications.

11
2011
U.S. Military Formally Adopts PEMF

The United States Military formally integrates PEMF into pain management protocols at rehabilitation centers — a significant institutional endorsement.

15
2015
10,000+ Indexed Studies on PubMed

PEMF becomes one of the most extensively researched non-invasive therapies in medicine, with a growing corpus of randomized controlled trials.

25
2025
20,000+ Studies · 250M+ Patients · 70+ PainFree Clinics

PEMF reaches global scale. PainFree operates the largest PEMF clinical network in the Middle East, now bringing the technology to the Philippines.

The Research

Published Evidence.
Peer-Reviewed.

Cochrane Review 2020

Gold Standard Evidence on Knee Osteoarthritis

16 randomized controlled trials on PEMF for knee osteoarthritis. Result: statistically significant reduction in pain and improved joint function versus control. Cochrane is the gold standard in evidence-based medicine.

Cochrane Central Register of Controlled Trials — April 2020
Double-Blind RCT — Back Pain (PMID: 12016348)

Chronic Back Pain & Whiplash: Statistically Significant Results

100 subjects with chronic back pain syndrome and 92 with whiplash syndrome. Double-blind, randomized design. PEMF demonstrated statistically significant pain reduction in both acute conditions.

Neurorehabilitation, PMID 12016348
Multicenter RCT 2025 (PMC11914662)

36% Pain Reduction vs. 10% in Standard Care

5 orthopedic clinics, n=91 subjects. PEMF group showed 36% pain reduction versus 10% in standard care. p<0.0001. Published in an indexed medical journal, available on PubMed Central.

PMC11914662 — Verifiable at pubmed.ncbi.nlm.nih.gov

Clinical Applications

16 Conditions.
One Device.

FDA clearance covers a broad range of musculoskeletal, neurological, and systemic conditions. Each represents a patient population already paying out-of-pocket for alternatives.

Herniated & Bulging Discs
Chronic Back & Neck Pain
Frozen Shoulder / Rotator Cuff
Knee & Hip Osteoarthritis
Sports Injuries & Fractures
Post-Surgical Rehabilitation
Fibromyalgia
Diabetic Neuropathy
Non-Healing Wounds & Ulcers
Neurological Rehab (Post-Stroke)
Parkinson's & MS (Emerging)
Chronic Fatigue & Sleep Disorders
Anxiety & Depression (Adjunct)
Chronic Migraine
Cartilage Degeneration
Elderly Pain & Osteoporosis

Each patient cohort completes 10–20 sessions. Chronic patients return. That's recurring revenue — not one-time transactions.

Next Step

Ready to Review
the Investment Brief?

Get the full package: device specs, ROI model, clinical protocols, training structure, and support terms.